Phase I, double-blind, placebo-controlled study of safety, tolerability and short-term efficacy of LY2409021 in patients with type 2 diabetes mellitus treated with diet and exercise or metformin.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2015
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 23 May 2012 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 23 May 2012 Actual initiation date (March 2008) and trial locations added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History